PainReform reaches 50% enrollment in second part of Phase 3 trial of PRF-110

PainReform announced it has reached the 50% enrollment target for the second part of Phase 3 clinical trial of PRF-110 in bunionectomy. In total, over 200 patients have been enrolled, of up to approximately 400 patients at eight clinical sites across the U.S. Ilan Hadar, Chief Executive Officer of PainReform, stated, “I am thrilled to announce that we have hit a critical milestone in our Phase 3 clinical trial of PRF-110 for bunionectomy, with 50% of the required participants now enrolled. Importantly, to date there have been no reported serious adverse events, underscoring PRF-110’s potential safety gathered until today. We’re on track to wrap up enrollment on schedule and are looking forward to sharing the early results in Q3 2024. We remain highly encouraged by the potential of PRF-110 to redefine the standard of care in the multibillion-dollar postoperative pain management market, as well as offering patients a compelling alternative to systemic opioids, which have contributed to the global opioid epidemic.”